Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-7547
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US ; volume:18 ; number:1 ; day:6 ; month:10 ; year:2020 ; pages:1-12 ; date:12.2020
Cost effectiveness and resource allocation ; 18, Heft 1 (6.10.2020), 1-12, 12.2020
- Urheber
-
Thokala, Praveen
Stevenson, Matt
Kumar, Varun M.
Ren, Shijie
Ellis, Alexandra G.
Chapman, Richard H.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12962-020-00234-8
- URN
-
urn:nbn:de:101:1-2020112216104735085465
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Thokala, Praveen
- Stevenson, Matt
- Kumar, Varun M.
- Ren, Shijie
- Ellis, Alexandra G.
- Chapman, Richard H.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden
Nusinersen: A Review in 5q Spinal Muscular Atrophy
Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy
Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
Correction to: Nusinersen: A Review in 5q Spinal Muscular Atrophy
Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
Evaluation of Metabolic Effects of Nusinersen in Patients with Spinal Muscular Atrophy
Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen
Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy
Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy
Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy
Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden
Nusinersen: A Review in 5q Spinal Muscular Atrophy
Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy
Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
Correction to: Nusinersen: A Review in 5q Spinal Muscular Atrophy
Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
Evaluation of Metabolic Effects of Nusinersen in Patients with Spinal Muscular Atrophy
Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen
Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy
Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy
Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy
Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden
Nusinersen: A Review in 5q Spinal Muscular Atrophy
Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy
Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
Correction to: Nusinersen: A Review in 5q Spinal Muscular Atrophy
Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
Evaluation of Metabolic Effects of Nusinersen in Patients with Spinal Muscular Atrophy
Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen
Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy
Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy